The Latest Breaking News from FDA

New Investigation Finds FDA's Food Side Is 'Broken'

Among experts on food safety, the consensus is that the FDA's food division isn't functional.

Reason · Apr 16, 2022

Noah Feldman: Will federal courts let states ban the abortion pill?

Even before the Supreme Court reverses Roe v. Wade, as most court watchers expect it to do this June, the legal battle about the aftermath of the decision is getting underway. By far the most consequential aspect of the fight is likely to be about state attempts to regulate medical…

Tribune News Service · Apr 16, 2022

COVID-19: First breathing test for detecting Coronavirus is authorized by FDA

The Food and Drug Administration (FDA) authorized the first test, InspectIR COVID-19 Breathalyzer, to detect COVID-19 through the breath for emergency use. Full story on Dynamite News:

Dynamite News · Apr 16, 2022

FDA authorizes 1st breath test for COVID-19 infection

The Food and Drug Administration has issued an emergency use authorization for what it says is the first device that can detect COVID-19 in breath samples

The Independent UK · Apr 14, 2022

FDA approves Covid breathalyzer that can detect cases in three minutes

Device can only be operated by trained professionals

The Independent UK · Apr 14, 2022

Covaxin’s Phase 2/3 clinical trials put on hold in the US

HYDERABAD: The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin in the US.

The Times of India · Apr 14, 2022

Baby formula shortage: What is causing supply issue and which stores are rationing products?

Out-of-stock per centages reached higher than 40 per cent in seven states in first week of April

The Independent UK · Apr 14, 2022

Covaxin trials in U.S. put on hold

WHO had announced suspension of the vaccine supplies through UN procurement agencies

The Hindu · Apr 14, 2022

Magenta Therapeutics Trims R&D, Cuts Workforce

Magenta Therapeutics Inc (NASDAQ:MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research investments, including the Company's planned dosing and administration optimization trial…

Benzinga · Apr 14, 2022

Adagio Pauses FDA Emergency Use Request For Its COVID-19 Therapy

Adagio Therapeutics Inc (NASDAQ:ADGI) provided an update on the anticipated timing for its Emergency Use Authorization (EUA) request for adintrevimab (ADG20) for the prevention and treatment of COVID-19.  Adintrevimab has demonstrated broadly neutralizing activity in vitro against variants of concern, including Alpha, Beta, Delta, Delta Plus, Gamma, and Omicron BA.1. But, the candidate has markedly…

Benzinga · Apr 14, 2022